Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of E7386 TR vs IR Tablets in Healthy Subjects
NCT04840927Phase 1Withdrawn
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of e7386 in solid tumor (2 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Plasma Concentration and 5 more. Planned start Apr 2021; status: withdrawn.
02
Drugs
e7386
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04840927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840927.